A multi-centre randomised, controlled clinical trial with 287 patients enrolled was completed between 2003 and 2008. It compared the safety and efficacy of NECT with eflornithine monotherapy, the current first-line treatment for stage 2 HAT. The final results of the study were published in The Lancet on July 4th, 2009. Download  
  Similar in efficacy and  safety profile

  • A cure rate of more than 96 % was shown to be comparable between the two treatments.
  • Patient follow-up 18 months after the treatment was at 93%. This is an excellent percentage given the remoteness and difficulty of access in the areas where the study was conducted.
  • The trial conclusively demonstrated that NECT is as well-tolerated as eflornithine monotherapy.


     Resistance less likely to develop

  • The two drugs have different modes of action, thus the risk of resistance is smaller as a mutual protection is expected.

   Less toxic than melarsoprol

  • NECT is a less toxic, more efficacious treatment than melarsoprol which is estimated to kill up to 5 % of treated patients, and has a documented high level of resistance. In 2008, this drug was still used for 50 % of the patients suffering from stage 2 HAT.

     Reduced risk of infections

  • With NECT the number of intravenous infusions has come down from 56 (with eflornithine monotherapy) to 14. This reduces the risk of infection linked to repeated intravenous infusions considerably – particularly also since the treatment needs to be implemented in remote areas with limited health infrastructure capacities.